SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001209191-23-053509
Filing Date
2023-10-24
Accepted
2023-10-24 19:43:50
Documents
2
Period of Report
2023-10-23

Document Format Files

Seq Description Document Type Size
1 FORM 3 SUBMISSION doc3.html 3  
1 FORM 3 SUBMISSION doc3.xml 3 2166
2 POA DOCUMENT poa.txt EX-24 3876
  Complete submission text file 0001209191-23-053509.txt   8023
Mailing Address C/O INTERCEPT PHARMACEUTICALS, INC. 450 WEST 15TH STREET, SUITE 505 NEW YORK NY 10011
Business Address C/O INTERCEPT PHARMACEUTICALS, INC. 450 WEST 15TH STREET, SUITE 505 NEW YORK NY 10011 646-747-1000
Benatti Luca (Reporting) CIK: 0001613842 (see all company filings)

State of Incorp.: DE | Fiscal Year End: 1231
Type: 3 | Act: 34 | File No.: 001-38890 | Film No.: 231343682

Mailing Address 601 GATEWAY BOULEVARD, SUITE 1250 SOUTH SAN FRANCISCO CA 94080
Business Address 601 GATEWAY BOULEVARD, SUITE 1250 SOUTH SAN FRANCISCO CA 94080 415-910-5717
Quince Therapeutics, Inc. (Issuer) CIK: 0001662774 (see all company filings)

IRS No.: 901024039 | State of Incorp.: CA | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)